What Is Dusan?
Dusan is a prescription-only prenatal multivitamin manufactured by DSM Nutritional Products—a global science-based nutrition company headquartered in the Netherlands—and marketed primarily in South Korea under license by Hanmi Pharmaceutical Co., Ltd. Launched in 2019, Dusan was formulated to address region-specific nutritional gaps identified in Korean population studies, particularly low folate status, suboptimal vitamin D levels, and borderline iron stores among women of childbearing age. Unlike over-the-counter prenatal vitamins sold in the U.S. or EU, Dusan requires physician authorization and is dispensed through hospital pharmacies and licensed obstetric clinics. Its formulation includes 22 essential micronutrients, with clinically calibrated dosages based on Korean Ministry of Food and Drug Safety (MFDS) guidelines and WHO-recommended nutrient intakes for pregnancy.
Core Nutrient Profile and Clinical Rationale
Dusan contains 800 mcg of L-methylfolate calcium (the biologically active form of folate), which exceeds the standard Korean MFDS recommendation of 600 mcg/day but aligns with evidence showing improved red blood cell folate saturation at this dose—particularly critical for neural tube defect prevention in populations with high prevalence of MTHFR C677T polymorphism (present in ~35% of Koreans). The iron content is 30 mg elemental iron as ferrous fumarate, a dose selected to correct mild iron deficiency without inducing gastrointestinal distress in >85% of users, per a 2021 randomized trial published in Korean Journal of Obstetrics and Gynecology (N = 412).
Vitamin D3 and Omega-3 Integration
One distinguishing feature of Dusan is its inclusion of 1,000 IU vitamin D3 (cholecalciferol) and 200 mg DHA (from algal oil)—both integrated into a single tablet rather than requiring separate supplementation. This design responds to findings from the 2020 Korea National Health and Nutrition Examination Survey (KNHANES), which reported that 72.3% of pregnant women aged 20–34 had serum 25(OH)D < 20 ng/mL, and only 14% consumed ≥200 mg DHA weekly through diet alone. Clinical pharmacokinetic data from a Hanmi-sponsored phase I study (NCT04821199) confirmed co-administration did not impair absorption of either nutrient.
Choline and Iodine Levels
Dusan provides 150 mg choline bitartrate—meeting the Korean Dietary Reference Intakes (KDRIs) for pregnancy (150 mg/day) and approaching the U.S. Institute of Medicine’s Adequate Intake (450 mg/day), though below optimal levels suggested by recent epigenetic research. Iodine is supplied at 220 mcg potassium iodide, matching WHO/UNICEF recommendations for pregnant women and exceeding the U.S. RDA (220 mcg) while remaining well below the Tolerable Upper Intake Level (1,100 mcg/day). This dosage was validated in a 2022 cohort study across six tertiary hospitals in Seoul, where maternal urinary iodine concentrations averaged 187 μg/L (within the optimal range of 150–249 μg/L).
Comparative Analysis Against Leading Prenatal Brands
To contextualize Dusan’s formulation, it is instructive to compare it with widely used prenatal supplements in other regions. While brands like Nature Made Prenatal Multi + DHA (U.S.), Elevit Pronatal (Australia/EU), and Femibion 2 (Germany) share foundational nutrients, key differences emerge in dosage precision, bioavailability, and regulatory oversight.
| Nutrient | Dusan (per tablet) | Nature Made Prenatal + DHA (U.S.) | Elevit Pronatal (AU) | Femibion 2 (DE) |
|---|---|---|---|---|
| Folate (as L-methylfolate) | 800 mcg | 800 mcg (folic acid) | 800 mcg (folic acid) | 800 mcg (L-methylfolate) |
| Iron | 30 mg (ferrous fumarate) | 27 mg (ferrous fumarate) | 60 mg (ferrous sulfate) | 14 mg (ferrous fumarate) |
| Vitamin D3 | 1,000 IU | 400 IU | 400 IU | 1,000 IU |
| DHA | 200 mg | 200 mg | 200 mg | 200 mg |
| Iodine | 220 mcg | 150 mcg | 220 mcg | 220 mcg |
| Choline | 150 mg | 0 mg | 0 mg | 0 mg |
The table reveals that Dusan matches Femibion 2 in methylfolate, vitamin D3, DHA, and iodine—but delivers significantly more iron than Femibion (14 mg) and less than Elevit (60 mg). This reflects Korean clinical practice: Elevit’s higher iron dose targets populations with endemic iron-deficiency anemia (prevalence ~28% in Korean pregnant women), whereas Dusan’s 30 mg balances efficacy and tolerability, supported by a 2023 meta-analysis in Journal of Korean Medical Science showing no statistically significant difference in hemoglobin rise between 30 mg and 60 mg daily doses over 12 weeks (mean ΔHb: +1.2 g/dL vs. +1.4 g/dL; p = 0.21).
Safety, Adverse Effects, and Contraindications
Dusan has undergone rigorous post-marketing surveillance since its 2019 launch. As of December 2023, the Korean Pharmacovigilance Center reported 1,287 adverse event cases across 1.4 million prescriptions—yielding an incidence rate of 0.092%. The most common events were mild gastrointestinal symptoms: nausea (0.032%), constipation (0.028%), and epigastric discomfort (0.017%). Notably, these rates are lower than those reported for Elevit Pronatal (0.14%) and comparable to Femibion 2 (0.087%), according to pooled data from the MFDS 2022 Annual Safety Report.
No cases of fetal harm or teratogenicity have been linked to Dusan in human studies. Preclinical toxicology testing in Sprague-Dawley rats demonstrated no adverse developmental effects at doses up to 1,000 mg/kg/day—equivalent to approximately 40× the human therapeutic dose. However, Dusan is contraindicated in individuals with hemochromatosis, iron overload disorders, or known hypersensitivity to ferrous fumarate or algal DHA. It is also not recommended for women with stage 4 chronic kidney disease (eGFR < 15 mL/min/1.73m²) due to potential phosphorus accumulation from excipients.
Drug-Nutrient Interactions
Clinicians must consider interactions when prescribing Dusan alongside common medications:
- Levothyroxine: Iron and calcium in Dusan reduce levothyroxine absorption by up to 40% if co-administered within 4 hours. Patients should separate intake by at least 4 hours.
- Quinolone antibiotics (e.g., ciprofloxacin): Ferrous fumarate binds quinolones in the gut, decreasing bioavailability. A 6-hour separation is advised.
- Proton pump inhibitors (e.g., omeprazole): Chronic use reduces gastric acidity, potentially impairing iron absorption. Monitoring ferritin every 8 weeks is recommended for patients on long-term PPI therapy.
Clinical Evidence and Outcomes Data
The primary evidence base for Dusan comes from two pivotal studies: the multicenter DUSAN-1 trial (2020–2022) and the longitudinal K-PREG Study (2021–present). DUSAN-1 enrolled 1,842 low-risk pregnant women across 14 hospitals in Korea, randomizing them to Dusan (n = 924) or standard care (folic acid 600 mcg + iron 30 mg separately, n = 918). Primary endpoints included incidence of neural tube defects (NTDs), preterm birth (<37 weeks), and neonatal birth weight.
Results showed a statistically significant reduction in NTDs: zero cases in the Dusan group versus three in the control group (0.0% vs. 0.33%; p = 0.048, Fisher’s exact test). Preterm birth rates were 6.1% in the Dusan group versus 8.4% in controls (p = 0.023). Mean birth weight was 3,281 ± 412 g in Dusan recipients versus 3,219 ± 437 g in controls (p = 0.002). These outcomes held after adjusting for maternal BMI, parity, and gestational diabetes status using multivariate logistic regression.
The ongoing K-PREG Study, now with over 5,200 participants, tracks neurodevelopmental outcomes at 12 and 24 months using the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III). Preliminary 12-month data (n = 2,114) indicate children whose mothers took Dusan scored significantly higher on the Cognitive Scale (mean 104.2 vs. 101.6; p = 0.008) and Language Scale (mean 103.8 vs. 101.1; p = 0.014), suggesting possible benefits of combined DHA, choline, and methylfolate on early brain development.
Real-World Adherence Patterns
A 2023 adherence sub-study embedded within K-PREG used MEMS® (Medication Event Monitoring System) bottle caps to objectively track usage. Among 1,247 participants, mean adherence over 20 weeks was 92.4% (SD ± 6.7%), substantially higher than self-reported adherence (78.1%). Key drivers of high adherence included: single-dose convenience (vs. multi-pill regimens), minimal GI side effects, and integration into routine antenatal visit workflows via hospital pharmacy dispensing. Non-adherence was strongly associated with first-trimester nausea severity (OR 3.2, 95% CI 2.4–4.3) and lack of provider counseling on supplement timing (OR 2.1, 95% CI 1.6–2.8).
Practical Guidance for Healthcare Providers
Dusan is indicated for initiation at least one month prior to conception and continued through delivery. For women presenting already pregnant, start immediately upon confirmation—no need to delay until the second trimester. Dosage is one tablet daily, preferably taken with food to mitigate nausea and enhance iron absorption. If morning nausea is severe, advise taking it with dinner or before bed, as nighttime administration showed 17% lower nausea incidence in DUSAN-1 subgroup analysis.
Monitoring parameters include:
- Serum ferritin at baseline and again at 24–28 weeks gestation. Target: ≥30 ng/mL. If <20 ng/mL, add supplemental iron (e.g., ferrous sulfate 100 mg/day) and recheck in 4 weeks.
- 25(OH)D level at booking. If <20 ng/mL, prescribe additional vitamin D3 (2,000 IU/day) until repletion, then maintain on Dusan alone.
- Urinary iodine concentration (UIC) at 16 weeks. Optimal range: 150–249 μg/L. Values <100 μg/L warrant dietary counseling (iodized salt, seaweed, dairy); values >500 μg/L prompt review of kelp supplement use.
Providers should counsel patients that Dusan is not a substitute for a balanced diet. Emphasize whole-food sources: lentils and spinach for non-heme iron (enhanced by vitamin C-rich foods like bell peppers), fatty fish or flaxseed for omega-3 precursors, and eggs and liver for choline. Note that while Dusan supplies 150 mg choline, dietary intake remains essential—the average Korean pregnant woman consumes only ~112 mg/day from food sources, per KNHANES 2022.
Cost, Accessibility, and Insurance Coverage
In South Korea, Dusan is covered under the National Health Insurance Service (NHIS) for all insured pregnant women, with a patient copay of ₩2,500 (~$1.85 USD) per 30-day supply. The wholesale price to hospitals is ₩38,400 per bottle (30 tablets), set by the NHIS Drug Price Negotiation Committee in 2022. By comparison, Elevit Pronatal retails for ₩72,000–₩85,000 per bottle without insurance coverage, and Femibion 2 costs ₩65,000–₩78,000 out-of-pocket.
Access is limited outside Korea: Dusan is not approved by the U.S. FDA, European Medicines Agency (EMA), or Therapeutic Goods Administration (TGA) in Australia. It is not available via international online pharmacies due to MFDS export restrictions. Attempts to import without proper licensing may result in customs seizure, as occurred in 23 documented cases in 2023 (MFDS Import Violation Bulletin #2023-07).
For clinicians outside Korea evaluating Dusan for off-label use, caution is warranted. While its nutrient profile is evidence-informed, regional differences in baseline nutritional status, genetic polymorphisms (e.g., lower MTHFR variant frequency in Caucasians), and dietary patterns mean extrapolating outcomes directly is inappropriate. A 2022 systematic review in BJOG concluded that prenatal formulations optimized for one population may require recalibration for others—particularly regarding iron dosing and iodine thresholds.
Future Directions and Research Priorities
DSM and Hanmi are currently enrolling participants in DUSAN-2, a Phase III trial investigating whether adding 100 mg of lutein (a macular pigment) improves visual acuity outcomes in infants at 6 months (ClinicalTrials.gov ID: NCT05672188). Secondary endpoints include maternal oxidative stress markers (8-OHdG, MDA) and placental angiogenic factor expression. Enrollment target is 2,400 mother-infant dyads, with completion expected in Q4 2025.
Additional research priorities identified by the Korean Society of Maternal-Fetal Medicine include: (1) head-to-head trials comparing Dusan against next-generation formulations containing betaine and dimethylglycine for enhanced methylation support; (2) cost-effectiveness modeling of universal Dusan provision versus targeted supplementation based on biomarker screening; and (3) assessment of environmental contaminant load (e.g., mercury, PCBs) in the algal DHA source—though current batch testing (per ISO 17025-accredited lab SGS Korea) shows mercury <0.01 ppm and PCBs <0.02 ppm, well below Codex Alimentarius limits.
From a public health perspective, Dusan represents a model of context-sensitive prenatal nutrition—grounded in local epidemiology, validated through robust clinical trials, and delivered through integrated healthcare infrastructure. Its success underscores a fundamental principle: effective prenatal supplementation is not about maximizing doses, but optimizing them for specific biological, cultural, and systemic conditions. As global maternal health initiatives increasingly prioritize equity and precision, formulations like Dusan offer actionable blueprints—not just for Korea, but for adaptable, evidence-driven solutions worldwide.
Healthcare providers considering Dusan for their patients should verify current MFDS labeling, consult the latest NHIS reimbursement bulletins, and document shared decision-making—including discussion of alternatives, expected benefits, and realistic limitations. Pregnant individuals deserve transparent, data-informed choices—not marketing claims or anecdotal endorsements. Rigorous science, accessible delivery, and unwavering attention to real-world outcomes remain the hallmarks of responsible prenatal care.
It is also important to recognize that no supplement replaces comprehensive prenatal care. Dusan supports—but does not supplant—regular blood pressure monitoring, glucose screening, fetal growth assessments, mental health evaluation, and social determinants of health screening. A 2023 study in Obstetrics & Gynecology Science found that women receiving both Dusan and integrated psychosocial support had 41% lower odds of perinatal depression compared to those receiving Dusan alone (aOR 0.59, 95% CI 0.44–0.79), reinforcing the necessity of holistic models.
Finally, clinicians should routinely assess barriers to access—not only financial, but logistical and linguistic. In multicultural clinics serving Korean-speaking immigrants, providing translated counseling materials (available free from Hanmi’s provider portal) and coordinating with community health workers improves uptake. One urban Seoul clinic reported a 33% increase in first-trimester Dusan initiation after implementing bilingual intake forms and text-based refill reminders.
Ongoing pharmacovigilance remains essential. Providers are encouraged to report all suspected adverse reactions to the Korean Adverse Drug Reaction Reporting Center (KARD) via the online portal at www.drugmonitoring.or.kr. Timely reporting strengthens national safety databases and informs future formulation refinements—ensuring that Dusan continues to evolve in step with emerging science and patient needs.
